Medicare Coverage Shift: How Novo Nordisk and Eli Lilly Win Big on Obesity Drug Access
A landmark policy shift is underway in the United States healthcare sector, as Medicare prepares to cover select obesity medications for the first time. This decision represents a pivotal moment for both public health and the pharmaceutical industry, unlocking a massive demographic of senior citizens who previously faced prohibitive out-of-pocket costs for these cutting-edge treatments. … Read more